Toward the Latest Advancements in Cardiac Regeneration Using Induced Pluripotent Stem Cells (iPSCs) Technology: Approaches and Challenges

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Aug 22

PMID 39175068

Authors

Seyedeh Parya Farboud

Ezzatollah Fathi

Behnaz Valipour

Raheleh Farahzadi

Affiliations

Soon will be listed here.

Abstract

A novel approach to treating heart failures was developed with the introduction of iPSC technology. Knowledge in regenerative medicine, developmental biology, and the identification of illnesses at the cellular level has exploded since the discovery of iPSCs. One of the most frequent causes of mortality associated with cardiovascular disease is the loss of cardiomyocytes (CMs), followed by heart failure. A possible treatment for heart failure involves restoring cardiac function and replacing damaged tissue with healthy, regenerated CMs. Significant strides in stem cell biology during the last ten years have transformed the in vitro study of human illness and enhanced our knowledge of the molecular pathways underlying human disease, regenerative medicine, and drug development. We seek to examine iPSC advancements in disease modeling, drug discovery, iPSC-Based cell treatments, and purification methods in this article.

References

Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K . Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci Rep. 2016; 6:19111. PMC: 4705488. DOI: 10.1038/srep19111. View

Japp A, Gulati A, Cook S, Cowie M, Prasad S . The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016; 67(25):2996-3010. DOI: 10.1016/j.jacc.2016.03.590. View

Ho C, Day S, Ashley E, Michels M, Pereira A, Jacoby D . Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138(14):1387-1398. PMC: 6170149. DOI: 10.1161/CIRCULATIONAHA.117.033200. View

Sayed N, Liu C, Wu J . Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol. 2016; 67(18):2161-2176. PMC: 5086255. DOI: 10.1016/j.jacc.2016.01.083. View

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

Liew L, Poh B, An O, Ho B, Lim C, Pang J . JAK2 as a surface marker for enrichment of human pluripotent stem cells-derived ventricular cardiomyocytes. Stem Cell Res Ther. 2023; 14(1):367. PMC: 10720068. DOI: 10.1186/s13287-023-03610-2. View

Huang G, Bisaria A, Wakefield D, Yamawaki T, Luo X, Zhang J . Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machinery. Stem Cell Reports. 2022; 18(1):220-236. PMC: 9860080. DOI: 10.1016/j.stemcr.2022.11.008. View

Tsujisaka Y, Hatani T, Okubo C, Ito R, Kimura A, Narita M . Purification of human iPSC-derived cells at large scale using microRNA switch and magnetic-activated cell sorting. Stem Cell Reports. 2022; 17(7):1772-1785. PMC: 9287667. DOI: 10.1016/j.stemcr.2022.05.003. View

Yang L, Soonpaa M, Adler E, Roepke T, Kattman S, Kennedy M . Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008; 453(7194):524-8. DOI: 10.1038/nature06894. View

10.

Musunuru K . An Overview of Genome Editing in Cardiovascular and Metabolic Diseases. Adv Exp Med Biol. 2022; 1396:3-16. DOI: 10.1007/978-981-19-5642-3_1. View

11.

Bai X . Stem Cell-Based Disease Modeling and Cell Therapy. Cells. 2020; 9(10). PMC: 7599677. DOI: 10.3390/cells9102193. View

12.

Rossler K, de Lange W, Mann M, Aballo T, Melby J, Zhang J . Lactate- and immunomagnetic-purified hiPSC-derived cardiomyocytes generate comparable engineered cardiac tissue constructs. JCI Insight. 2023; 9(1). PMC: 10906451. DOI: 10.1172/jci.insight.172168. View

13.

Corrado D, van Tintelen P, McKenna W, Hauer R, Anastastakis A, Asimaki A . Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J. 2019; 41(14):1414-1429. PMC: 7138528. DOI: 10.1093/eurheartj/ehz669. View

14.

Jeon S, Kim H, Chun K, Oh J, Kwon C, Choi H . Human induced pluripotent stem cell line YCMi007-A generated from a dilated cardiomyopathy patient with a heterozygous dominant c.613C > T (p. Arg205Trp) variant of the TNNT2 gene. Stem Cell Res. 2023; 67:103048. DOI: 10.1016/j.scr.2023.103048. View

15.

Sen-Chowdhry S, Morgan R, Chambers J, McKenna W . Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010; 61:233-53. DOI: 10.1146/annurev.med.052208.130419. View

16.

Crotti L, Celano G, Dagradi F, Schwartz P . Congenital long QT syndrome. Orphanet J Rare Dis. 2008; 3:18. PMC: 2474834. DOI: 10.1186/1750-1172-3-18. View

17.

Lewandowski J, Rozwadowska N, Kolanowski T, Malcher A, Zimna A, Rugowska A . The impact of in vitro cell culture duration on the maturation of human cardiomyocytes derived from induced pluripotent stem cells of myogenic origin. Cell Transplant. 2018; 27(7):1047-1067. PMC: 6158549. DOI: 10.1177/0963689718779346. View

18.

Lakdawala N, Winterfield J, Funke B . Dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2012; 6(1):228-37. PMC: 3603701. DOI: 10.1161/CIRCEP.111.962050. View

19.

Djouadi F, Lecarpentier Y, Hebert J, Charron P, Bastin J, Coirault C . A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res. 2009; 84(1):83-90. DOI: 10.1093/cvr/cvp183. View

20.

Blair N, Barker R . Making it personal: the prospects for autologous pluripotent stem cell-derived therapies. Regen Med. 2016; 11(5):423-5. DOI: 10.2217/rme-2016-0057. View